From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas

In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xueyuan, Turcan, Sevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157002/
https://www.ncbi.nlm.nih.gov/pubmed/34067729
http://dx.doi.org/10.3390/cells10051225
_version_ 1783699581478895616
author Sun, Xueyuan
Turcan, Sevin
author_facet Sun, Xueyuan
Turcan, Sevin
author_sort Sun, Xueyuan
collection PubMed
description In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ.
format Online
Article
Text
id pubmed-8157002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81570022021-05-28 From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas Sun, Xueyuan Turcan, Sevin Cells Review In this review, we discuss the use of the alkylating agent temozolomide (TMZ) in the treatment of IDH-mutant gliomas. We describe the challenges associated with TMZ in clinical (drug resistance and tumor recurrence) and preclinical settings (variabilities associated with in vitro models) in treating IDH-mutant glioma. Lastly, we summarize the emerging therapeutic targets that can potentially be used in combination with TMZ. MDPI 2021-05-17 /pmc/articles/PMC8157002/ /pubmed/34067729 http://dx.doi.org/10.3390/cells10051225 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sun, Xueyuan
Turcan, Sevin
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
title From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
title_full From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
title_fullStr From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
title_full_unstemmed From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
title_short From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
title_sort from laboratory studies to clinical trials: temozolomide use in idh-mutant gliomas
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157002/
https://www.ncbi.nlm.nih.gov/pubmed/34067729
http://dx.doi.org/10.3390/cells10051225
work_keys_str_mv AT sunxueyuan fromlaboratorystudiestoclinicaltrialstemozolomideuseinidhmutantgliomas
AT turcansevin fromlaboratorystudiestoclinicaltrialstemozolomideuseinidhmutantgliomas

Ejemplares similares